Curis, Inc. Announces Issuance of U.S. Patent Covering CUDC-101 Composition of Matter for Novel HDAC/EGFR/Her2 Inhibitor

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced the issuance of U.S. Patent Number 7,547,781, entitled “Quinazoline Based EGFR Inhibitors Containing a Zinc Binding Moiety.” The patent covers a genus of compounds that includes CUDC-101, Curis’ HDAC/EGFR/Her2 inhibitor, which is currently in a Phase I clinical trial.

Back to news